Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1847-1852

  Skeie, Geir Olve ^a   Muller, B ^a   Haugarvoll, K ^a   Larsen, J P ^b,c   Tysnes, O B ^a,c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Alcohol; Coffee; Occupation; Parkinson's disease; Risk factor; Smoking

Indexed keywords

ALCOHOL; CAFFEINE; PESTICIDE;

ADULT; AGED; AGRICULTURE; ALCOHOL CONSUMPTION; ARTICLE; BODY POSTURE; CONTROLLED STUDY; DIETARY INTAKE; EDUCATIONAL STATUS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FEMALE; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; OCCUPATION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TOBACCO; TREMOR;

ALCOHOL DRINKING; COFFEE; DRINKING BEHAVIOR; GAIT; HUMANS; PARKINSON DISEASE; POSTURAL BALANCE; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 77956857663     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23178     Document Type: Article

References (38)

1. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54 (Suppl 5):S21-23.
2. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517-536. (Pubitemid 36543283)
3. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60:389-398.
4. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-670.
5. Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 2007;62:137-144.
6. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81-104.
7. McCulloch CC, Kay DM, Factor SA, et al. Exploring gene-environment interactions in Parkinson's disease. Hum Genet 2008; 123:257-265.
8. Alves G, Muller B, Herlofson K, et al. The Norwegian ParkWest study. Incidence of Parkinson's disease in Norway. The Norwegian Park West study. J Neurol Neurosurg Psychiatry 2009;80: 891-897.
9. Paulsen JS, Duff K. Extending MCI beyond Alzheimer disease. Neurology 2009;72:1116-1117.
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
11. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S., Marsden CD, Calne DM, Lieberman A, editors. Recent development in Parkinson's disease, Florham Park, NJ: MacMillan Health Care Information; 1987. p 153-163.
12. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
13. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
14. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007;64:1635-1640. (Pubitemid 350106766)
15. Korchounov A, Schipper HI, Preobrazhenskaya IS, Kessler KR, Yakhno NN. Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease. Mov Disord 2004;19:1059-1064.
16. Gossrau G, Herting B, Mockel S, et al. Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm 2006;113:331-337.
17. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130 (Part 7):1787-1798.
18. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002;62:347-376. (Pubitemid 37046679)
19. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008;70 (Part 2):1403-1410.
20. Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 2006;21: 1066-1072.
21. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
22. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001;50: 780-786.
23. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88-95.
24. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
25. Ascherio A, Chen H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 2003;61(Supp 6):S51-S54. (Pubitemid 37505548)
26. Ross GW, Abbott RD, Petrovitch H, et al.. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-2679.
27. Hellenbrand W, Boeing H, Robra BP, et al. Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996;47:644-650.
28. Pauly JR, Charriez CM, Guseva MV, Scheff SW. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann N Y Acad Sci 2004;1035:316-334.
29. Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4- phenyl-2,3,6- tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988;132:589-591.
30. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003;984:224-232.
31. Parain K, Marchand V, Dumery B, Hirsch E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res 2001;890:347-350. (Pubitemid 32115489)
32. Singh S, Singh K, Patel S, et al. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinson's disease phenotype in mouse. Brain Res 2008;1207:193-206.
33. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol 2007;74:1224-1234.
34. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation 2007;116:1306-1317.
35. Brighina L, Schneider NK, Lesnick TG, et al. alpha-Synuclein, alcohol use disorders, and Parkinson disease: A case-control study. Parkinsonism Relat Disord 2009;15:430-434.
36. Dhillon AS, Tarbutton GL, Levin JL, et al. Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 2008;13:37-48.
37. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-1350.
38. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.